MAESTRAL - A Prospective, Multinational, Multicenter, Randomized, Double Blind, Double Dummy, Controlled Study Comparing the Efficacy and Safety of Moxifloxacin to That of Amoxicillin Clavulanic Acid for the Treatment of Subjects With Acute Exacerbations of Chronic Bronchitis.

Trial Profile

MAESTRAL - A Prospective, Multinational, Multicenter, Randomized, Double Blind, Double Dummy, Controlled Study Comparing the Efficacy and Safety of Moxifloxacin to That of Amoxicillin Clavulanic Acid for the Treatment of Subjects With Acute Exacerbations of Chronic Bronchitis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2014

At a glance

  • Drugs Moxifloxacin (Primary) ; Amoxicillin/clavulanic acid
  • Indications Acute exacerbations of chronic bronchitis; Haemophilus infections; Pneumococcal infections; Staphylococcal infections
  • Focus Therapeutic Use
  • Acronyms MAESTRAL
  • Sponsors Bayer
  • Most Recent Events

    • 01 Dec 2011 Results published in the European Respiratory Journal.
    • 25 Sep 2011 Primary endpoint 'Clinical-failure' has been met.
    • 25 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society, according to a Bayer HealthCare media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top